NEW YORK, May 20 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (the "Company") (Nasdaq: KERX) announced today the appointment of Ron Bentsur as Chief Executive Officer of the Company. It is also anticipated that Ron Bentsur will join the Company's Board of Directors at the annual meeting of the board on June 16, 2009.
Michael P. Tarnok, Interim Chairman of the Company's Board of Directors, stated, "On behalf of the Board, I want to welcome Ron Bentsur to Keryx. Ron is an experienced biopharmaceutical executive who has a proven track-record in creating significant shareholder value. We believe that Ron's leadership abilities and longstanding relationships with the investment, research and banking communities make him ideally-suited to unlock the inherent value of our late-stage pipeline."
Mr. Bentsur commented, "I am extremely excited for this opportunity to lead Keryx at this key juncture for the Company. We have two late-stage clinical drug candidates, each with compelling phase 2 data, that we believe have been under appreciated for quite some time. I look forward to introducing our exciting story to the investor community and working to enhance our asset values for the benefit of all of our stakeholders."
Ron Bentsur has more than a decade of experience in the biotech industry. Most recently, Mr. Bentsur served as CEO of XTL Biopharmaceuticals, a position he held from January 2006 until April 2009. Prior to his tenure at XTL, Mr. Bentsur was with the Company from 2000-2006, serving as the Company's Chief Financial Officer from June 2003 until his departure in January 2006. From July 1998 to October 2000, Mr. Bentsur served as Director of Technology Investment Banking at Leumi Underwriters, where he was responsible for all technology/ biotechnology private placement and advisory transactions. From
|SOURCE Keryx Biopharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved